NEW YORK — Luigi Mangione is heading to federal court Friday for a crucial hearing that could determine whether prosecutors pursue the death penalty in connection with the murder of UnitedHealthcare CEO Brian Thompson. Mangione’s defense team claims the government has compromised his case by turning his December 2024 arrest into a media spectacle, suggesting they expressed intentions to seek capital punishment even before formal charges were brought against him.
In their defense filings, Mangione’s attorneys argue that the murder by firearm charge, which opens the door for the death penalty, is legally unsound. They also proposed that the public frenzy and pretrial publicity have prejudiced their client’s right to a fair trial. Federal prosecutors counter this position, asserting that the murder charge is valid and that concerns about media coverage can be managed through thorough juror questioning during the selection process.
Facing both federal and state murder charges, Mangione has pleaded not guilty to all allegations, which could result in a life sentence if he is convicted. This marks Mangione’s first appearance in Manhattan federal court since his arraignment on April 25. The defense is expected to contest specific evidence gathered during his arrest, potentially including a firearm linked to the crime and a notebook with concerning statements referring to an intent to harm a health insurance executive.
U.S. District Judge Margaret Garnett is slated to address the evidentiary issues and may also establish a trial date during Friday’s proceedings. Mangione has garnered a loyal following, with supporters venturing to court dressed in green or holding signs that express solidarity with him.
Among the key issues is the defense’s claim that police conducted an illegal search when they recovered items from Mangione’s backpack prior to securing a warrant. Prosecutors argue that the items would have been discovered eventually, underlining that the search was conducted out of public safety concerns.
Thompson, 50, was shot on December 4, 2024, as he was approaching a Manhattan hotel for a UnitedHealth Group event. Surveillance footage captured the moment a masked gunman approached him from behind, and police reports indicated that certain phrases referenced in the ammunition echoed tactics used by insurers to avoid payouts.
The circumstances surrounding Mangione’s arrest also added layers of controversy. He was apprehended five days after Thompson’s death at a McDonald’s in Altoona, Pennsylvania, about 230 miles from New York City. His efforts in state court have seen some success; a judge recently dismissed state terrorism charges against him, highlighting ongoing challenges for both sides.
U.S. Attorney General Pam Bondi, who has publicly championed the case, announced last year that the federal government would seek the death penalty, branding the act as a “premeditated, cold-blooded assassination that shocked America.” In contrast, Mangione’s legal team alleges Bondi’s statements and her previous lobbying ties to UnitedHealthcare’s parent company have tainted the indictment process, claiming that such factors introduced bias against their client.
Federal prosecutors rebuffed these assertions, defending the integrity of the legal procedures leading to Mangione’s indictment. They insisted that the defense’s claims were unfounded and aimed at undermining the seriousness of the case. As Friday’s hearing unfolds, the implications for both Mangione’s future and the broader legal narrative surrounding capital punishment will come into sharper focus.